You are here

biotech

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

BioSpace

Neumora Therapeutics

Rome Therapeutics

Generate Biomedicines

Flag link:

‘It’s Like Ross Was Planning This Project.’ Perot Sr.’s HQ Finds New Life as Biotech Development

‘It’s Like Ross Was Planning This Project.’ Perot Sr.’s HQ Finds New Life as Biotech Development

D Magazine

Flag link:

Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech

Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech

Stat

Vivek Ramaswamy

2024 Presidential election

Flag link:

Mass Layoffs Continue Across The Biotech Sector. What Does This Mean For Pharma’s Future?

Mass Layoffs Continue Across The Biotech Sector. What Does This Mean For Pharma’s Future?

Forbes

Flag link:

Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit

Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit

Stat

venture capital

The Column Group

Flag link:

Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit

Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit

Stat

venture capital

Flag link:

Biopharma sector still growing despite layoff wave, Stifel report finds

Biopharma sector still growing despite layoff wave, Stifel report finds

BioPharma Dive

Flag link:

Early-stage biotech funding on pace to drop 40% in 2023, HSBC report shows

Early-stage biotech funding on pace to drop 40% in 2023, HSBC report shows

BioPharma Dive

Flag link:

Biophama's flotation haul creeps higher

Biophama's flotation haul creeps higher

EP Vantage

Apogee Therapeutics

CytoMed Therapeutics

Intensity Therapeutics

Mineralys Therapeutics

Paragon Therapeutics

Sagimet Biosciences

Structure Therapeutics

Turnstone Biologics

Flag link:

Women left out of VC club fight for their identity, pulling each other up one by one

Women left out of VC club fight for their identity, pulling each other up one by one

Fierce Biotech

venture capital

Norwest Venture Partners

Flag link:

Biotech IPOs in 2023: Shaping the Future of Innovation

Biotech IPOs in 2023: Shaping the Future of Innovation

Xtalks

Flag link:

Serial biotech founder Tim Springer on investing in startups and democratizing antibody research

Serial biotech founder Tim Springer on investing in startups and democratizing antibody research

BioPharma Dive

Flag link:

3 Key Biotech Trends for 2023 And Beyond

3 Key Biotech Trends for 2023 And Beyond

Motley Fool

artificial intelligence

clinical trials

drug development

Flag link:

So you think you can go public? Few biotechs dance with Wall Street

So you think you can go public? Few biotechs dance with Wall Street

Fierce Biotech

Structure Therapeutics

Mineralys Therapeutics

Coya Therapeutics

Flag link:

After a record run, fewer biotechs are going public. Here’s how they’re performing.

After a record run, fewer biotechs are going public. Here’s how they’re performing.

BioPharma Dive

Flag link:

Biotechs see 'staggering' 87% rise in layoffs during Q1, on pace to overtake 2022

Biotechs see 'staggering' 87% rise in layoffs during Q1, on pace to overtake 2022

Fierce Biotech

Flag link:

Biotech layoffs gather pace as industry downturn persists

Biotech layoffs gather pace as industry downturn persists

BioPharma Dive

Jounce Therapeutics

Fate Therapeutics

Molecular Templates

Sorrento Therapeutics

Flag link:

Biopharma Rallies Behind FDA After Texas Abortion Pill Ruling

Biopharma Rallies Behind FDA After Texas Abortion Pill Ruling

BioSpace

Flag link:

Biotech leaders 'cannot stay quiet' as judge blocks abortion pill approval

Biotech leaders 'cannot stay quiet' as judge blocks abortion pill approval

Fierce Biotech

Flag link:

Pages